Tous les patients traités sont en rémission clinique et sans récidive après au moins deux ans de suivi dans la partie Phase I de l’essai randomisé dans les cancers de la tête et du cou HPV-négatifs ...

All patients in the treatment arm remain disease-free after a minimum of 2-year follow-up in the randomized Phase I trial in resected HPV-negative locally advanced head and neck cancer – Demonstrating ...

Reference is further made to stock exchange announcement of yesterday regarding the successful private placement of new shares in the company for gross proceeds of approximately NOK 297,644,400, ...

“When people are diagnosed with metastatic pancreatic adenocarcinoma, the most important question remains: how long will they have with their loved ones,” said Dr. Vincent Chung, Medical Oncologist, ...

acquired a total of 18,007 shares in Moreld. Of these, 953 shares were acquired at a price of NOK 13.20 per share, and 17,054 shares were acquired at a price of NOK 13.26 per share. Following these ...

Paris, France - (30 May 2025) - PROACTIS SA (ISIN code: FR0004052561) announces the postponement of the publication, originally scheduled for May 30, 2025, of its results and Annual Financial Report ...

semisubmersible drilling rigs, capable of working worldwide. This announcement is not an offer for sale of securities in the United States. The securities referred to in this announcement have not ...

La Hulpe, Belgium - 30 May 2025, 10:30 p.m. CET - Banqup Group SA, formerly Unifiedpost Group SA, (Euronext: UPG) (Banqup, Company), a leading provider of integrated business communications solutions, ...

(ii) Ratified the appointment of Deloitte Certified Public Accountants S.A. as independent auditors for the year ending December 31, 2025. Following the Annual Meeting, the Board of Directors of the ...

expected and the new target implementation date is end of June 2025. The Company has for this purpose obtained a formal extension of the waiver from the senior secured lender and working capital ...

For more information, please visit www.cadeler.com. To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.

Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today ...